Berlex
Executive Summary
Sends Quinaglute Dura-Tabs "Dear Doctor" letter May 27 to 46,443 health care professionals in response to FDA's April 2 warning letter on company promotion of the quinidine gluconate sustained-release tablets ("The Pink Sheet" April 12, p. 12). The letter notes that the Berlex product has "not been demonstrated to be safer or more effective that any other sustained-release quinidine gluconate tablet with an 'AB' rating"; that Quinaglute Dura-Tabs "should not be universally dosed BID...as suggested in our previous promotional materials"; and that "there are no adequate and well-controlled studies to support our previous claims that Quinaglute Dura-Tabs Tablets have either a lower incidence of GI side effects or a lower discontinuation rate than any other Class I antiarrhythmic product".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth